4d Molecular Therapeutics In (FDMT) Held by Superinvestors
4D MOLECULAR THERAPEUTICS IN (FDMT) is currently held by 1 superinvestors tracked by InsiderSet, with a combined reported market value of approximately $8.17M based on the latest available SEC Form 13F filings for the quarter ended June 30, 2026.
Renaissance Technologies LLC is currently the largest disclosed institutional shareholder of FDMT tracked by InsiderSet, reporting ownership valued at approximately $8.17M in its June 30, 2026 SEC Form 13F filing. Based on current market prices and the latest disclosed share count, the position is now estimated to be worth approximately $6.64M, representing an estimated loss of -18.80% since the filing period.
The top 10 institutional shareholders tracked on this page collectively account for approximately 100% of the total disclosed FDMT value among the investors covered in this analysis. Major shareholders include Renaissance Technologies LLC, and several other long-term asset managers with concentrated positions in 4D MOLECULAR THERAPEUTICS IN (FDMT).
This page ranks the largest institutional FDMT shareholders using publicly disclosed SEC Form 13F data, including reported values, estimated current holding values, portfolio allocation percentages, ownership concentration metrics, and historical holding changes across major hedge funds and investment firms.
| Name | Investor/Manager | Portfolio % | Quantity | Reported Balance | Current Estimated Value | Gain/loss Since Filing | Estimated Portfolio Performance |
|---|---|---|---|---|---|---|---|
| Renaissance Technologies LLC | Jim Simons | 0.01% | 614,573 | $8,173,821 | $6,637,388 | -$1,536,433 | -18.80% |
Frequently asked questions about FDMT
Who are the largest superinvestors holding FDMT?
The largest superinvestors holding FDMT in the latest SEC Form 13F filings include Renaissance Technologies LLC. InsiderSet ranks these superinvestors by their latest reported FDMT position.
What does the FDMT superinvestors page include?
This page tracks FDMT positions reported by a curated group of notable institutional investors and fund managers through SEC Form 13F. 4D MOLECULAR THERAPEUTICS IN (FDMT) on this page reflects disclosed 13F holdings among those superinvestors, not every institutional shareholder of the stock.
How many superinvestors hold FDMT?
InsiderSet currently tracks 1 superinvestors reporting FDMT holdings in the latest available 13F data. This is the curated set on this page, not the total number of institutions that own FDMT.
How much FDMT stock do superinvestors hold?
Superinvestors tracked by InsiderSet disclosed approximately $8.17M in FDMT holdings for Q2 2026. This figure is reported 13F value as of the filing period, not necessarily today's market value, and it covers the curated superinvestors on this page rather than every institutional filer.
When were FDMT superinvestor holdings last updated?
The latest FDMT superinvestor holdings on InsiderSet are based on SEC Form 13F filings for the quarter ended June 30, 2026. Form 13F filings are generally reported after the quarter ends, so the holdings shown represent the latest publicly disclosed positions rather than real-time holdings.
Are superinvestor FDMT holdings real-time?
No. Form 13F data is not real-time. It represents positions reported by these superinvestors as of the end of the reporting quarter. A superinvestor may have changed its FDMT position after the reporting date.
Are superinvestors buying or selling FDMT?
Buying and selling can be analyzed by comparing FDMT positions across consecutive 13F reporting periods. InsiderSet's FDMT Ownership Changes page shows institutions that increased, reduced, initiated, or exited positions based on reported 13F holdings. View FDMT ownership changes.
How have superinvestor FDMT holdings changed over time?
InsiderSet tracks FDMT holdings among these superinvestors across multiple 13F reporting periods, so holder counts, reported value, and reported shares can be compared over time.